Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KPRX
KPRX | US
2.58
USD0.08
3.20%
KPRX | US
Loading StockChartView...
About KPRX
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
08/06/2026
Close
2.58
Open
2.51
High
2.60
Low
2.51
Kiora Pharmaceuticals Inc. a clinical-stage specialty pharmaceutical company develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301 a potential vision-restoring small molecule which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101 an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis as well as for treating non-infectious posterior uveitis; and KIO-201 an eye drop which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals Inc. and changed its name to Kiora Pharmaceuticals Inc. in November 2021. Kiora Pharmaceuticals Inc. was incorporated in 1998 and is headquartered in Encinitas California.
View LessKPRX | US
Risk
65.3
Sharpe
-0.34
Luna's Score
49/100
Recommendation
Hold
Luna says (KPRX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
63.1%1 month
65.3%3 months
85.2%6 months
67.1%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
0.21
Fwd. PE
2.41
Price to book
0.31
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-1.03
Ent. to rev.
569.41
PEG
-
Other Fundamentals
EBITDA
6.32M
MarketCap
7.66M
MarketCap(USD)
7.66M
Div. yield
-
Op. margin
-12.12K
Erngs. growth
-
Rev. growth
-
Ret. on equity
13.69
Short ratio
0.31
Short perc.
0.14
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.40
Range1M
0.48
Range3M
1.14
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.45
Price X volume
50.86K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.03 | 0.53 | Cheaper |
| Ent. to Revenue | 569.41 | 3,967.00 | Cheaper |
| PE Ratio | 0.21 | 41.03 | Cheaper |
| Price to Book | 0.31 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 85.20 | 72.80 | Par |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 7.66M | 3.66B | Emerging |
